Advertisement
"Bill has been a tremendous asset to Bioheart during his tenure and we aresorry to see him leave in order to pursue other interests," said Leonhardt."Under his leadership, Bioheart became a publicly traded company and advancedthe base of clinical evidence regarding our MyoCell(R) clinical cell therapy,including initiation of our potentially pivotal Phase II/III MARVEL Trial inthe US and Europe. I look forward to a greater level of involvement as wecontinue to pursue regulatory approval and commercialization of this therapyto treat congestive heart failure patients, as well as, drive the developmentof future generation products. We look to the future with great anticipation."
Advertisement
ABOUT BIOHEART
Bioheart, Inc. (NASDAQ: BHRT) is a biotechnology company focused on thediscovery, development and, subject to regulatory approval, commercializationof autologous cell therapies for the treatment of chronic and acute heartdamage. Its lead product candidate, MyoCell(R), is an innovative clinicalcell therapy designed to populate regions of scar tissue within a patient'sheart with new living cells for the purpose of improving cardiac function inchronic heart failure patients. The Company's pipeline includes multipleproduct candidates for the treatment of heart damage, including Bioheart AcuteCell Therapy, an autologous, adipose cell treatment for acute heart damage,and MyoCell(R) SDF-1, a therapy utilizing autologous cells that aregenetically modified to express additional potentially therapeutic growthproteins. For more information on Bioheart, visit http://www.bioheartinc.com.
MyoCell and MyoCell SDF-1 are trademarks of Bioheart, Inc.
Forward Looking Statements:
Except for historical matters contained herein, statements made in thispress release are forward-looking and are made pursuant to the safe harborprovisions of the Private Securities Litigation Reform Act of 1995. Withoutlimiting the generality of the foregoing, words such as "may", "will", "to","plan", "expect", "believe", "anticipate", "intend", "could", "would","estimate", or "continue" or the negative other variations thereof orcomparable terminology are intended to identify forward-looking statements.
Investors and others are cautioned that a variety of factors, includingcertain risks, may affect our business and cause actual results to differmaterially from those set forth in the forward-looking statements. These riskfactors include, without limitation, (i) our ability to secure additionalfinancing; (ii) the timely success and completion of our clinical trials;(iii) the occurrence of any unacceptable side effects during or afterpreclinical and clinical testing of our product candidates; (iv) regulatoryapproval of our product candidates; (v) our dependence on the success of ourlead product candidate; (vi) our inability to predict the extent of our futurelosses or if or when we will become profitable; (vii) our ability to protectour intellectual property rights; (viii) our inability to predict the extentof our future losses or if or when we will become profitable; and (viii)intense competition . The company is also subject to the risks anduncertainties described in its filings with t
